MaxCyte Partners with Adicet Bio for Gamma Delta T Cell Therapy Platform License Agreement
ByAinvest
Tuesday, Aug 5, 2025 3:31 pm ET1min read
ACET--
The agreement aims to enhance Adicet Bio's ability to develop and commercialize its gamma delta T cell therapies. MaxCyte's Flow Electroporation® technology and ExPERT™ platform are designed to support complex and scalable cell engineering, delivering high transfection efficiency and cell viability [2].
Maher Masoud, President and Chief Executive Officer of MaxCyte, stated, "We are pleased to support Adicet Bio as they expand their allogeneic gamma delta T cell manufacturing capabilities to include non-viral gene editing delivery. This collaboration underscores the versatility of our platform and its ability to enable the development of next-generation cell therapy candidates with increased efficiency and accessibility" [1].
MaxCyte will receive platform licensing fees and program-related revenue as part of the agreement. However, the exact terms and conditions of the agreement, including the potential revenue streams, were not disclosed [1].
Adicet Bio has developed a proprietary manufacturing process to activate and expand distinct subsets of gamma delta T cells, enabling scalable production of its off-the-shelf, allogeneic cell therapies for use on demand in the clinical setting. The company's approach combines non-viral gene editing with a robust expansion platform to deliver potent cell therapy products with the potential to treat a broad range of cancers and autoimmune disorders [1].
The SPL agreement between MaxCyte and Adicet Bio is a significant step in advancing the development of next-generation cell therapies. It highlights the potential of MaxCyte's platform technology in enabling the efficient and scalable production of cell-based therapeutics [1].
References:
[1] https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-signs-platform-license-agreement-adicet-bio
[2] https://www.morningstar.com/news/globe-newswire/9504081/maxcyte-signs-platform-license-agreement-with-adicet-bio
MXCT--
MaxCyte has signed a strategic platform license agreement with Adicet Bio, granting non-exclusive rights to use MaxCyte's Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes. In return, MaxCyte will receive platform licensing fees and program-related revenue. The agreement aims to enhance the development of Adicet Bio's allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company, has signed a strategic platform license (SPL) agreement with Adicet Bio, Inc., a biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Under the terms of the agreement, Adicet Bio will obtain non-exclusive research, clinical, and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform [1].The agreement aims to enhance Adicet Bio's ability to develop and commercialize its gamma delta T cell therapies. MaxCyte's Flow Electroporation® technology and ExPERT™ platform are designed to support complex and scalable cell engineering, delivering high transfection efficiency and cell viability [2].
Maher Masoud, President and Chief Executive Officer of MaxCyte, stated, "We are pleased to support Adicet Bio as they expand their allogeneic gamma delta T cell manufacturing capabilities to include non-viral gene editing delivery. This collaboration underscores the versatility of our platform and its ability to enable the development of next-generation cell therapy candidates with increased efficiency and accessibility" [1].
MaxCyte will receive platform licensing fees and program-related revenue as part of the agreement. However, the exact terms and conditions of the agreement, including the potential revenue streams, were not disclosed [1].
Adicet Bio has developed a proprietary manufacturing process to activate and expand distinct subsets of gamma delta T cells, enabling scalable production of its off-the-shelf, allogeneic cell therapies for use on demand in the clinical setting. The company's approach combines non-viral gene editing with a robust expansion platform to deliver potent cell therapy products with the potential to treat a broad range of cancers and autoimmune disorders [1].
The SPL agreement between MaxCyte and Adicet Bio is a significant step in advancing the development of next-generation cell therapies. It highlights the potential of MaxCyte's platform technology in enabling the efficient and scalable production of cell-based therapeutics [1].
References:
[1] https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-signs-platform-license-agreement-adicet-bio
[2] https://www.morningstar.com/news/globe-newswire/9504081/maxcyte-signs-platform-license-agreement-with-adicet-bio
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet